Comparative Pharmacology
Head-to-head clinical analysis: ENSKYCE versus NORLESTRIN 21 2 5 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENSKYCE versus NORLESTRIN 21 2 5 50.
ENSKYCE vs NORLESTRIN 21 2.5/50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENSKYCE (fospropofol disodium) is a prodrug of propofol. It is hydrolyzed by alkaline phosphatases to release propofol, which acts as a positive allosteric modulator of GABA-A receptors, enhancing chloride conductance and producing sedation and anesthesia.
Combination oral contraceptive containing an estrogen (ethinyl estradiol) and a progestin (norethindrone acetate). Inhibits ovulation by suppressing gonadotropin release. Increases viscosity of cervical mucus, impeding sperm penetration, and alters endometrial receptivity.
2 g IV every 8 hours over 5 hours on days 1-3 of each 21-day cycle
One tablet orally once daily for 21 days, followed by 7 days off, then repeat.
None Documented
None Documented
12 hours (terminal); allows once-daily dosing in most patients
Norethindrone: 8 hours (terminal); Ethinyl estradiol: 13 hours (terminal). Clinical context: Steady-state achieved after 3-5 days; dosing interval based on once-daily administration.
Renal: ~70% unchanged; Biliary/Fecal: ~20% as metabolites
Renal: 50-60% as metabolites (glucuronide and sulfate conjugates of norethindrone and ethinyl estradiol); fecal: 30-40% via biliary elimination; <1% unchanged.
Category C
Category C
Oral Contraceptive
Oral Contraceptive